Share-based Payment Arrangement, Expense of Structure Therapeutics Inc. from 31 Mar 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Structure Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2022 to 30 Sep 2025.
  • Structure Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $7,495,000, a 24% increase year-over-year.
  • Structure Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $26,753,000, a 78% increase year-over-year.
  • Structure Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $18,794,000, a 129% increase from 2023.
  • Structure Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8,191,000, a 226% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Structure Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $26,753,000 $7,495,000 +$1,472,000 +24% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $25,281,000 $7,509,000 +$3,313,000 +79% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $21,968,000 $5,918,000 +$3,174,000 +116% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $18,794,000 $5,831,000 +$3,733,000 +178% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $15,061,000 $6,023,000 +$4,165,000 +224% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $10,896,000 $4,196,000 +$2,494,000 +147% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $8,402,000 $2,744,000 +$211,000 +8.3% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $8,191,000 $2,098,000 +$1,475,000 +237% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $6,716,000 $1,858,000 +$1,230,000 +196% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $5,486,000 $1,702,000 +$1,059,000 +165% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $4,427,000 $2,533,000 +$1,913,000 +309% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $2,514,000 $623,000 01 Oct 2022 31 Dec 2022 10-K 08 Mar 2024 2023 FY
Q3 2022 $628,000 01 Jul 2022 30 Sep 2022 10-Q 17 Nov 2023 2023 Q3
Q2 2022 $643,000 01 Apr 2022 30 Jun 2022 10-Q/A 17 Nov 2023 2023 Q2
Q1 2022 $620,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1

Structure Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $18,794,000 +$10,603,000 +129% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $8,191,000 +$5,677,000 +226% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $2,514,000 01 Jan 2022 31 Dec 2022 10-K 08 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.